Holen Sie sich die Stockscreener-App
2.03
12.15%
0.22
Schlusskurs vom Vortag:
$1.81
Offen:
$2.14
24-Stunden-Volumen:
15.79M
Relative Volume:
12.22
Marktkapitalisierung:
$103.00M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-67.68M
KGV:
-1.2229
EPS:
-1.66
Netto-Cashflow:
$-54.24M
1W Leistung:
+70.59%
1M Leistung:
+87.96%
6M Leistung:
-33.00%
1J Leistung:
-83.91%
1-Tages-Spanne:
$1.65
$2.16
1-Wochen-Bereich:
$1.24
$2.16
52-Wochen-Spanne:
$0.9857
$13.50
Cabaletta Bio Inc Stock (CABA) Company Profile
Firmenname
Cabaletta Bio Inc
Sektor
Branche
Telefon
(267) 759-3100
Adresse
2929 ARCH STREET, PHILADELPHIA, PA
Vergleichen Sie CABA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CABA
Cabaletta Bio Inc
|
2.03 | 60.38M | 0 | -67.68M | -54.24M | -1.66 |
|
ONC
Beigene Ltd Adr
|
228.38 | 25.07B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.65 | 109.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.27 | 36.39M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
594.32 | 56.98B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
71.31 | 5.39B | 0 | -153.72M | -103.81M | -2.00 |
Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-20 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-12-19 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-10-10 | Eingeleitet | UBS | Buy |
| 2024-02-05 | Eingeleitet | Jefferies | Buy |
| 2023-11-29 | Eingeleitet | William Blair | Outperform |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-19 | Eingeleitet | Stifel | Buy |
| 2023-09-05 | Eingeleitet | Citigroup | Buy |
| 2023-07-18 | Eingeleitet | Guggenheim | Buy |
| 2023-01-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-08-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-06-30 | Eingeleitet | Mizuho | Buy |
| 2021-01-08 | Eingeleitet | Chardan Capital Markets | Buy |
| 2020-10-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-19 | Eingeleitet | Cowen | Outperform |
| 2019-11-19 | Eingeleitet | Evercore ISI | Outperform |
| 2019-11-19 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Guggenheim Forecasts Strong Price Appreciation for Cabaletta Bio (NASDAQ:CABA) Stock - Defense World
Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CABA Stock News: Citigroup Lowers Price Target but Maintains Buy - GuruFocus
CABA: Guggenheim Raises Price Target for Cabaletta Bio to $25 | CABA Stock News - GuruFocus
UBS Adjusts Price Target on Cabaletta Bio to $6 From $7, Maintains Buy Rating - marketscreener.com
Cabaletta Bio’s Strategic Advancements and Trial Successes Drive Buy Rating - TipRanks
Cabaletta Bio (CABA) Price Target Slashed by Citi, Keeps Buy Rating | CABA Stock News - GuruFocus
Cabaletta Bio Extends Gains Premarket as FDA Meeting Fuels Expectations for Myositis BLA Submission - marketscreener.com
41,626 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Acquired by Stifel Financial Corp - Defense World
Cabaletta Bio (CABA) Expected to Announce Earnings on Wednesday - MarketBeat
Cabaletta Bio Stock Surges To 2-Month High On Autoimmune Therapy Progress; Retail’s Pleased - Asianet Newsable
Fred Alger Management LLC Sells 1,803,170 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
CABA: Guggenheim Raises Price Target to $25, Maintains Buy Ratin - GuruFocus
CABA: Guggenheim Raises Price Target to $25, Maintains Buy Rating | CABA Stock News - GuruFocus
Guggenheim Increases Price Target for Cabaletta Bio (CABA) to $2 - GuruFocus
Cabaletta Bio (CABA) Targets 2027 for Rese-cel BLA Submission | - GuruFocus
Cabaletta Bio Inc (CABA) Reports Q1 EPS Miss at -0.64, No Revenue Recorded - GuruFocus
Cabaletta Bio Announces 2027 Rese-Cel BLA Submission Anticipated In Myositis Following Recent FDA Alignment On Registrational Cohorts - marketscreener.com
Cabaletta Bio, Inc. SEC 10-Q Report - TradingView
Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent ... - Eagle-Tribune
Breakthrough: FDA Grants RMAT Status to Cabaletta's Myositis Therapy, Accelerating Path to 2027 BLA - Stock Titan
Barclays PLC Boosts Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio (CABA) to Release Quarterly Earnings on Wednesday - Defense World
Wells Fargo & Company MN Purchases 16,250 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
LAWSUITS FILED AGAINST CRNC, CABA and FBJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
LAWSUITS FILED AGAINST BMBL, CABA and RIVNJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
LAWSUITS FILED AGAINST CRNC, CABA and AFRMJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
LAWSUITS FILED AGAINST CLVT, CRNC and CABAJakubowitz Law Pursues Shareholders Claims - ACCESS Newswire
Envestnet Asset Management Inc. Trims Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Renaissance Technologies LLC Takes Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
T. Rowe Price Investment Management Inc. Buys 400,282 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
230,161 Shares in Cabaletta Bio, Inc. (NASDAQ:CABA) Purchased by Renaissance Technologies LLC - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
It would be worthwhile to take a closer look at Cabaletta Bio Inc (CABA) - uspostnews.com
Market Recap: Cabaletta Bio Inc (CABA)’s Negative Momentum, Closing at 1.25 - DWinneX
Cabaletta Bio Inc’s Banking’s 100-Day Moving Average at 2.0189: Will the Stock Break Through? - investchronicle.com
Walleye Capital LLC Reduces Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat
JPMorgan Chase & Co. Cuts Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Geode Capital Management LLC Buys 16,058 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
CABA’s Financial Health: Exploring Cabaletta Bio Inc’s Debt-to-Equity Ratio of 1.79 - investchronicle.com
Is Cabaletta Bio Inc (CABA) a good investment opportunity? - uspostnews.com
American Superconductor Corp (AMSC) requires closer examination - uspostnews.com
Aehr Test Systems (AEHR) shows promising results - uspostnews.com
Wellington Management Group LLP Has $409,000 Stock Position in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World
William Blair Increases Earnings Estimates for Cabaletta Bio - MarketBeat
HC Wainwright Weighs in on Cabaletta Bio FY2029 Earnings - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Cabaletta Bio to Present Pioneering Clinical Data on Rese-cel at Major Scientific Conferences - MSN
Finanzdaten der Cabaletta Bio Inc-Aktie (CABA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.54%
7.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):